ATE253936T1 - Glutathion-reduktase zur behandlung und prophylaxe von aids - Google Patents

Glutathion-reduktase zur behandlung und prophylaxe von aids

Info

Publication number
ATE253936T1
ATE253936T1 AT00920596T AT00920596T ATE253936T1 AT E253936 T1 ATE253936 T1 AT E253936T1 AT 00920596 T AT00920596 T AT 00920596T AT 00920596 T AT00920596 T AT 00920596T AT E253936 T1 ATE253936 T1 AT E253936T1
Authority
AT
Austria
Prior art keywords
aids
treatment
prophylaxis
glutathione reductase
reductase
Prior art date
Application number
AT00920596T
Other languages
English (en)
Inventor
Raffaele Ansovini
Original Assignee
Raffaele Ansovini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raffaele Ansovini filed Critical Raffaele Ansovini
Application granted granted Critical
Publication of ATE253936T1 publication Critical patent/ATE253936T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01007—Glutathione-disulfide reductase (1.8.1.7), i.e. glutathione reductase (NADPH)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00920596T 1999-05-21 2000-03-28 Glutathion-reduktase zur behandlung und prophylaxe von aids ATE253936T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001122A IT1312569B1 (it) 1999-05-21 1999-05-21 Uso dell'enzima gssg reduttasi per il trattamento terapeutico e laprofilassi di pazienti infettati da hiv.
PCT/EP2000/002703 WO2000071146A2 (en) 1999-05-21 2000-03-28 Glutathione reductase for therapy and prophylaxis of aids

Publications (1)

Publication Number Publication Date
ATE253936T1 true ATE253936T1 (de) 2003-11-15

Family

ID=11383014

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920596T ATE253936T1 (de) 1999-05-21 2000-03-28 Glutathion-reduktase zur behandlung und prophylaxe von aids

Country Status (12)

Country Link
US (1) US7045323B2 (de)
EP (1) EP1178819B1 (de)
JP (1) JP2003519088A (de)
AT (1) ATE253936T1 (de)
AU (1) AU4111600A (de)
DE (1) DE60006519T2 (de)
DK (1) DK1178819T3 (de)
ES (1) ES2211532T3 (de)
HK (1) HK1045258B (de)
IT (1) IT1312569B1 (de)
PT (1) PT1178819E (de)
WO (1) WO2000071146A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1312569B1 (it) 1999-05-21 2002-04-22 Raffaele Ansovini Uso dell'enzima gssg reduttasi per il trattamento terapeutico e laprofilassi di pazienti infettati da hiv.
ITMI20010760A1 (it) * 2001-04-10 2002-10-10 Raffaele Ansovini Associazione di enzimi coadiuvante nella terapia con interferone
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
US20120244212A1 (en) * 2004-11-07 2012-09-27 Frederick Timothy Guilford Enhanced method and composition for the treatment of hiv+ tuberculosis patients with anti-retroviral drugs and liposomal encapsulation for delivery of reduced glutathione
DE602006020434D1 (de) * 2005-05-17 2011-04-14 Santen Pharmaceutical Co Ltd Ein aminderivat als wirkstoff enthaltender angiogeneseinhibitor
IT1393875B1 (it) * 2009-04-29 2012-05-11 Medestea Res & Production S P A Coniugato glutatione reduttasi-peg e suo impiego come medicamento antinfluenzale
IT1401504B1 (it) * 2010-08-02 2013-07-26 Cattarini Mastelli Composizione comprendente glutatione reduttasi e glutatione ossidato

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2928417A1 (de) * 1979-07-12 1981-01-29 Schering Ag Trijodierte basen
US5843641A (en) * 1993-02-26 1998-12-01 Massachusetts Institute Of Technology Methods for the daignosis, of familial amyotrophic lateral sclerosis
EP0759303B1 (de) * 1994-04-22 2002-10-16 Yamanouchi Pharmaceutical Co. Ltd. Kolon-spezifisches arzneistofffreisetzungssystem
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
US5827886A (en) * 1997-05-07 1998-10-27 Thione International, Inc. Composition for relief of arthritis-induced symptoms
IT1312569B1 (it) 1999-05-21 2002-04-22 Raffaele Ansovini Uso dell'enzima gssg reduttasi per il trattamento terapeutico e laprofilassi di pazienti infettati da hiv.

Also Published As

Publication number Publication date
DE60006519D1 (de) 2003-12-18
ITMI991122A1 (it) 2000-11-21
AU4111600A (en) 2000-12-12
EP1178819B1 (de) 2003-11-12
EP1178819A2 (de) 2002-02-13
WO2000071146A3 (en) 2001-03-01
DK1178819T3 (da) 2004-02-02
PT1178819E (pt) 2004-04-30
IT1312569B1 (it) 2002-04-22
ES2211532T3 (es) 2004-07-16
DE60006519T2 (de) 2004-06-03
JP2003519088A (ja) 2003-06-17
US20040223958A1 (en) 2004-11-11
HK1045258A1 (en) 2002-11-22
WO2000071146A2 (en) 2000-11-30
US7045323B2 (en) 2006-05-16
HK1045258B (zh) 2004-04-02

Similar Documents

Publication Publication Date Title
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE451921T1 (de) Phenylindole zur behandlung von hiv
MXPA05006196A (es) Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
MXPA04003796A (es) Tioacetamidas sustituidas.
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
ATE253936T1 (de) Glutathion-reduktase zur behandlung und prophylaxe von aids
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE422944T1 (de) Superoxiddismutas-mimetika zur behandlung von augenerkrankungen
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
WO2003045428A3 (de) Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
WO2004045519A3 (en) Induction of apoptosis by hiv-1 infected monocytic cells
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
ATE314854T1 (de) Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs
AU7477101A (en) Human site-1 protease promoter
AU2002303133A1 (en) Peroxiredoxin drugs for treatment of hiv-1 infection and methods of use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1178819

Country of ref document: EP

REN Ceased due to non-payment of the annual fee